BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BiOptix Announces Expansion of Innovators Program at Molecular Med TRI-CON 2013


2/13/2013 8:54:07 AM

BOULDER, Colo., and SAN FRANCISCO, Feb. 12, 2013 /PRNewswire/ -- BiOptix in conjunction with Molecular Med TRI-CON 2013 will officially announce the expansion of the BiOptix Innovators Program, a unique-to-the-industry "try before you buy" instrument demo program that encourages researchers and institutions to become acquainted with the new BiOptix 404pi, the first commercially available SPR instrument to incorporate phase-based common path interferometry technology.

During the event, Ken Wilczek, Vice President of Sales and Marketing for BiOptix remarked: "We are actively seeking and qualifying researchers and institutions who would like to experience a new way of evaluating and purchasing an SPR instrument." "Through the marriage of excellent customer service and world-class technology, BiOptix aims to simplify the SPR instrument evaluation process, building a true partnership with scientific researchers to demonstrate the capabilities of the 404pi, a 21st century benchmark for new and innovative label-free SPR instrumentation." "Quite simply, this is not your father's SPR instrumentthe BiOptix 404pi will change how you think and work with SPR." continued Wilczek.

Additional details about the BiOptix Innovators Program, including how you or your institution can request a demo of the BiOptix 404pi can be found at: http://www.bioptix.com/products/innovators-program or by contacting BiOptix at: 303-545-5550 x 125.

In addition to Molecular Med TRI-CON 2013, BiOptix will be highlighting the 404pi at the following events during the first half of 2013:

  • PepTalk 2013 The Protein Science Week
  • BioPhysical Society 57th Annual Meeting
  • IBC's Biopharmaceutical Development & Production Week
  • US HUPO
  • AACR The American Association for Cancer Research
  • 9th Annual Pegs The Essential Protein Engineering Summit
  • 2013 Merck Technology Symposia
  • TIDES 2013 Oligonucleotide and Peptide Research, Technology and Product Development
  • 2013 Bristol-Myers Squibb Vendor & Technology Symposia

Surface Plasmon Resonance is an advanced and highly sensitive optical technology that can measure refractive index changes on a sensor chip's gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants. BiOptix has developed and patented a novel ultra-sensitive detection platform known as Enhanced Surface Plasmon resonance, or ESPR. Unlike traditional SPR, ESPR instrumentation from BiOptix enables the high sensitivity of SPR with the high stability and lower noise of common path interferometry.

About BiOptix

BiOptix Diagnostics Corporation is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures and Rusnano. BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interactionwith high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at: www.bioptix.com

SOURCE BiOptix Diagnostics Corporation



Read at BioSpace.com

BiOptix
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES